Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
MK0677 · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| MK0677 | DRUG | - |
* Patients must have probable Alzheimer's disease of mild or moderate severity. * A brain scan and laboratory results must be consistent with Alzheimer's disease. * The patient must be otherwise medically healthy.
Top 20 of 24 competitors
MK0677 is an investigational small molecule being studied for the treatment of Alzheimer's Disease. It is in Phase 2 clinical development and has not been approved by regulatory authorities. The drug is being developed by Merck & Company, Inc. (MRK).
The specific molecular target of MK0677 is not disclosed in the available information. The drug is a small molecule being investigated for its potential effects in Alzheimer's Disease, but its mechanism of action has not been publicly detailed.
MK0677 is being developed by Merck & Company, Inc., a pharmaceutical company traded on the New York Stock Exchange under the ticker symbol MRK. The drug is currently in Phase 2 clinical trials for Alzheimer's Disease.
MK0677 is in Phase 2 clinical development. It is an investigational drug for Alzheimer's Disease and has not been approved by the FDA or other regulatory agencies. One Phase 2 trial has been completed, involving 512 participants.
MK0677 has one completed Phase 2 clinical trial registered as NCT00074529, titled 'Study of MK0677 for the Treatment of Alzheimer's Disease (0677-030)(COMPLETED)'. The trial enrolled 512 participants aged 50 years and older with Alzheimer's Disease. It was a randomized, double-blind, uncontrolled study.
No alternative names for MK0677 have been identified in the available information. The drug is referred to solely as MK0677 in clinical trial records and development documentation.